Literature DB >> 28396501

Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy.

Michele Covella1, Ethan J Rowin1, Nicholas S Hill1, Ioana R Preston1, Alberto Milan1, Alexander R Opotowsky1, Barry J Maron1, Martin S Maron1, Bradley A Maron2.   

Abstract

BACKGROUND: There are limited data on the prevalence, pathophysiology, and management implications of pulmonary hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced heart failure. METHODS AND
RESULTS: To assess the clinical significance of measured cardiopulmonary hemodynamics in hypertrophic cardiomyopathy patients with heart failure, we retrospectively assessed right heart catheterization data in 162 consecutive patients with outflow tract gradients (median [interquartile range], 90 mm Hg [70-110 mm Hg]), 59±11 years old, and 49% men, predominately New York Heart Association class III/IV status. Pulmonary hypertension (mean pulmonary artery pressure, ≥25 mm Hg) was present in 82 patients (51%), including 29 (18%) regarded as moderate-severe (mean pulmonary artery pressure, ≥35 mm Hg) and 28 (34%) also had increased pulmonary vascular resistance >3.0 WU. The pulmonary artery wedge pressure was ≤15 mm Hg in 54%, indicating that left atrial hypertension was absent in a majority of patients. Notably, 9 patients (11%) met hemodynamic criteria for precapillary pulmonary hypertension (mean pulmonary artery pressure, ≥25 mm Hg; pulmonary vascular resistance, >3.0 WU; pulmonary artery wedge pressure, ≤15 mm Hg). Over a median follow-up of 327 days (90-743 days) after surgical myectomy (or alcohol septal ablation), 92% and 95% of patients with or without preoperative pulmonary hypertension, respectively, were asymptomatic or mildly symptomatic. One postoperative death occurred in a 59-year-old woman with acute respiratory failure and mean pulmonary artery pressure of 65 mm Hg.
CONCLUSIONS: Pulmonary hypertension was common in obstructive hypertrophic cardiomyopathy patients with advanced heart failure. Although possibly a contributor to preoperative heart failure, pulmonary hypertension did not significantly influence clinical and surgical outcome. Notably, a novel patient subgroup was identified with resting invasive hemodynamics consistent with pulmonary vascular disease.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cardiomyopathy, hypertrophic; hypertension, pulmonary; pulmonary artery; pulmonary heart disease

Mesh:

Substances:

Year:  2017        PMID: 28396501      PMCID: PMC5390526          DOI: 10.1161/CIRCHEARTFAILURE.116.003689

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  19 in total

Review 1.  How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice.

Authors:  Barry J Maron; Ethan J Rowin; Susan A Casey; Martin S Maron
Journal:  JAMA Cardiol       Date:  2016-04-01       Impact factor: 14.676

2.  The invasive cardiopulmonary exercise test.

Authors:  Bradley A Maron; Barbara A Cockrill; Aaron B Waxman; David M Systrom
Journal:  Circulation       Date:  2013-03-12       Impact factor: 29.690

3.  Accuracy of noninvasively determined pulmonary artery systolic pressure.

Authors:  Jeffrey M Testani; Martin G St John Sutton; Susan E Wiegers; Amit V Khera; Richard P Shannon; James N Kirkpatrick
Journal:  Am J Cardiol       Date:  2010-03-05       Impact factor: 2.778

4.  Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy.

Authors:  Kevin C Ong; Jeffrey B Geske; Virginia B Hebl; Rick A Nishimura; Hartzell V Schaff; Michael J Ackerman; Kyle W Klarich; Konstantinos C Siontis; Thais Coutinho; Joseph A Dearani; Steve R Ommen; Bernard J Gersh
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2016-02-27       Impact factor: 6.875

Review 5.  Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Authors:  Bradley A Maron
Journal:  Can J Cardiol       Date:  2014-09-28       Impact factor: 5.223

6.  Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; Iacopo Olivotto; Susan A Casey; Anna Arretini; Benedetta Tomberli; Ross F Garberich; Mark S Link; Raymond H M Chan; John R Lesser; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094

7.  Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary
Journal:  Circulation       Date:  2016-02-12       Impact factor: 29.690

8.  Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.

Authors:  Martin S Maron; Iacopo Olivotto; Andrey G Zenovich; Mark S Link; Natesa G Pandian; Jeffery T Kuvin; Stefano Nistri; Franco Cecchi; James E Udelson; Barry J Maron
Journal:  Circulation       Date:  2006-11-06       Impact factor: 29.690

9.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

10.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

View more
  14 in total

1.  Network Analysis to Risk Stratify Patients With Exercise Intolerance.

Authors:  William M Oldham; Rudolf K F Oliveira; Rui-Sheng Wang; Alexander R Opotowsky; David M Rubins; Jon Hainer; Bradley M Wertheim; George A Alba; Gaurav Choudhary; Adrienn Tornyos; Calum A MacRae; Joseph Loscalzo; Jane A Leopold; Aaron B Waxman; Horst Olschewski; Gabor Kovacs; David M Systrom; Bradley A Maron
Journal:  Circ Res       Date:  2018-02-05       Impact factor: 17.367

Review 2.  Endothelial Senescence: A New Age in Pulmonary Hypertension.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  Circ Res       Date:  2022-03-17       Impact factor: 17.367

Review 3.  Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.

Authors:  Christopher J Rhodes; Andrew J Sweatt; Bradley A Maron
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

4.  Surgical outcome for hypertrophic cardiomyopathy patients with extreme interventricular septal thickness: a propensity score matched study.

Authors:  Changwei Ren; Shengwei Wang; Jianbo Yu; Hongchang Guo; Hehe Ma; Zhipeng Wei; Kemin Liu; Yongqiang Lai
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

5.  Frataxin deficiency promotes endothelial senescence in pulmonary hypertension.

Authors:  Miranda K Culley; Jingsi Zhao; Yi Yin Tai; Ying Tang; Dror Perk; Vinny Negi; Qiujun Yu; Chen-Shan C Woodcock; Adam Handen; Gil Speyer; Seungchan Kim; Yen-Chun Lai; Taijyu Satoh; Annie Mm Watson; Yassmin Al Aaraj; John Sembrat; Mauricio Rojas; Dmitry Goncharov; Elena A Goncharova; Omar F Khan; Daniel G Anderson; James E Dahlman; Aditi U Gurkar; Robert Lafyatis; Ahmed U Fayyaz; Margaret M Redfield; Mark T Gladwin; Marlene Rabinovitch; Mingxia Gu; Thomas Bertero; Stephen Y Chan
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 14.808

6.  Association between severity of obstructive sleep apnea and high-sensitivity C-reactive protein in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Juan Wang; Haobo Xu; Chao Guo; Xin Duan; Fenghuan Hu; Weixian Yang; Jingang Cui; Lei Song; Yushi Chun; Jiansong Yuan; Shubin Qiao
Journal:  Clin Cardiol       Date:  2020-05-27       Impact factor: 2.882

Review 7.  Clinical presentations of hypertrophic cardiomyopathy and implications for therapy.

Authors:  Carles Díez-López; Joel Salazar-Mendiguchía
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

8.  Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy.

Authors:  Min Zhao; Min Liu; Jeffrey P Leal; Benjamin M W Tsui; Dean F Wong; Martin G Pomper; Yun Zhou
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

9.  Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line.

Authors:  Marc A Simon; Bradley A Maron
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

10.  Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.

Authors:  Bradley A Maron; Rui-Sheng Wang; Sergei Shevtsov; Stavros G Drakos; Elena Arons; Omar Wever-Pinzon; Gordon S Huggins; Andriy O Samokhin; William M Oldham; Yasmine Aguib; Magdi H Yacoub; Ethan J Rowin; Barry J Maron; Martin S Maron; Joseph Loscalzo
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.